LONDON (ShareCast) - (Sharecast News) - Faron Pharmaceuticals announced the appointment of Jurriaan Dekkers as its chief financial officer on Monday, strengthening its senior leadership team as the clinical-stage biotech prepared its lead drug candidate, bexmarilimab, for registrational studies.
Dekkers was joining with more than two decades of experience in biopharma and healthcare, including senior roles at ProQR Therapeutics and AstraZeneca, where he previously served as CFO in the Netherlands and as CEO of Acerta Pharma.

The AIM-traded firm said Dekkers also previously held finance positions at DaVita Medical Group and Sandvik, and currently sat on the supervisory and audit committees of Dutch children's charity Stichting Kinderpostzegels.

He holds a master's degree in economics and is a certified public auditor.

Chief executive Juho Jalkanen said the appointment would support Faron's next phase of development.

"We are very happy to welcome Jurriaan into Faron's team in this exciting growth phase of Faron.

"His experience and proven track record of fundraising and strategic and commercial growth initiatives will support the advancement of our lead asset bexmarilimab as it enters the registrational study," he said.

Dekkers was replacing Yrjö Wichmann, who would retire after a transition period ending in the first quarter of 2026.

At 1201 GMT, shares in Faron Pharmaceuticals were down 4.58% at 181.3p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE